Railway Pension Investments Ltd reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 82.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,360 shares of the company's stock after selling 211,120 shares during the quarter. Railway Pension Investments Ltd owned 0.06% of IDEXX Laboratories worth $23,879,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. J.Safra Asset Management Corp purchased a new position in IDEXX Laboratories in the 2nd quarter valued at $25,000. SHP Wealth Management purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth $26,000. Elevation Wealth Partners LLC grew its holdings in shares of IDEXX Laboratories by 188.2% during the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company's stock worth $26,000 after buying an additional 32 shares in the last quarter. Virtus Advisers LLC acquired a new stake in shares of IDEXX Laboratories in the third quarter valued at about $26,000. Finally, WealthCollab LLC purchased a new position in shares of IDEXX Laboratories in the second quarter worth about $30,000. Hedge funds and other institutional investors own 87.84% of the company's stock.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on IDXX. Citigroup upped their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a research note on Wednesday, August 5th. UBS Group boosted their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a "neutral" rating in a report on Wednesday, August 5th. Wall Street Zen cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. Barclays reduced their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 11th. Finally, Weiss Ratings lowered IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a research note on Thursday. Six research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, IDEXX Laboratories has an average rating of "Moderate Buy" and a consensus price target of $747.00.
Read Our Latest Stock Report on IDXX
IDEXX Laboratories Stock Up 0.3%
IDXX stock opened at $556.69 on Tuesday. The firm has a market cap of $43.86 billion, a PE ratio of 39.15, a PEG ratio of 2.96 and a beta of 1.54. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. The firm's 50 day moving average price is $559.23 and its 200-day moving average price is $572.70. IDEXX Laboratories, Inc. has a one year low of $518.55 and a one year high of $769.98.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, topping the consensus estimate of $3.94 by $0.33. The company had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The firm's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the prior year, the business posted $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.
About IDEXX Laboratories
(
Free Report)
IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.
IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
